Final Report - TRKCANCER (The anoikis suppressor TrKB as a target for novel anti-cancer agents)
Project ID: 37758Funded under: FP6-LIFESCIHEALTH
This is the final report for the TRKCANCER project. At the end of the contract, TrkB was not validated as a target for anti-cancer drugs, but encouraging results obtained yet and critical experiments still ongoing. Three potent and selective TrkB inhibitors were selected for in vivo evaluation of antimetastatic properties. New mouse models for metastasis were in use and several alternative models were identified. New potential biomarkers for metastasis were identified as critical factors of TrkB pathway.
Download application/pdf (72142)
Record Number: 12236 / Last updated on: 2011-04-14